LXEO

Lexeo Therapeutics Inc.

Chardan Capital reiterated a "buy" rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday...

The consensus price target hints at a 108.2% upside potential for Lexeo Therapeutics, Inc. (LXEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Analysts raised price targets and boosted approval odds after the FDA signaled support for a faster review process, citing strong safety and efficacy data in early trials of Lexeo’s treatment for Friedreich’s ataxia–related heart disease.

The company stated that data from a planned pivotal study will be pooled with data from the ongoing Phase I/II studies of LX2006 to support an approval application to the U.S. Food and Drug Administration for the therapy.

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.

Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ('Satellos' or the 'Company'), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...

Shares of Lexeo Therapeutics (NASDAQ: LXEO) lost 26% on Monday after it reported positive interim data from two cohorts of the phase I/II SUNRISE-FA study evaluating LX2006, an investigational gene...